Association of in utero antibiotic exposure on childhood ear infection trajectories: Results from a national birth cohort study

Association Between In-Utero Exposure to Antibiotics and Offspring's Hearing Loss: A Systematic Review and Meta-Analysis

Objectives: Antibiotic exposure during pregnancy is common, accounting for over 80% of all medications prescribed. Antibiotics in pregnancy are linked to increased childhood disease risk, through direct toxicity or potentially microbiome dysbiosis. This systematic review investigated the relationship between in-utero exposure to antibiotics and childhood hearing loss. Methods: We searched Ovid Medline, Embase, and PubMed for studies examining antibiotic exposure during pregnancy and its associations with hearing loss in offspring. Studies with children whose mothers had data on antibiotic exposure during pregnancy were selected. The meta-analysis calculated (1) pooled prevalence of childhood hearing loss and (2) pooled odds ratios (ORs) for associations between in-utero exposure to antibiotics and childhood hearing loss. Results: Of 1244 studies identified, 18 met the inclusion criteria. Among 161,053 children exposed in-utero to antibiotics, 4368 developed hearing loss. The pooled prevalence of childhood hearing loss was 0.9% (95% CI 0.0-2.8%, I2 = 99.6%). In-utero exposure to antibiotics was associated with an increased risk of childhood hearing loss (pooled OR 1.2, 95% CI 1.1 to 1.3, I2 = 15.4%). Aminoglycoside exposure during pregnancy was associated with a higher risk of hearing loss (pooled OR 1.2, 95% CI 1.1 to 1.3, I2 = 38.4%), while exposure to other antibiotic classes showed no association. Conclusions: The prevalence of childhood hearing loss among those exposed to antibiotics during pregnancy is high. Although the overall risk appears modest, aminoglycosides are linked to a significantly higher risk, suggesting maternal aminoglycoside exposure may indicate a risk for child hearing loss. Further research is needed to clarify causal pathways and long-term effects of in-utero exposure to antibiotics.

Rethinking Medication Safety in Pregnancy: How Target Trial Emulation and Real-World Data Bridge the Evidence Gap

OBJECTIVES

The exclusion of pregnant women and infants from many randomized controlled trials (RCTs) has left critical gaps in medication safety, complicating clinical decision-making during these sensitive life stages. This commentary explores target trial emulation using real-world data as a robust alternative for advancing medication safety research when RCTs are not feasible.

METHODS

Target trial emulation replicates the design principles of RCTs within observational data, accounting for the dynamic nature of medication exposure across gestational stages and adjusting for time-varying confounders. While challenges such as unmeasured confounding, selection bias, and violations of positivity assumptions remain, this method provides crucial insights to address current evidence gaps.

RESULTS

Information on medication exposure effects will be obtained, which will inform safer medication guidelines in pregnancy and infancy. Future research integrating artificial intelligence-driven tools, open science practices, and robust data governance frameworks will further strengthen the reliability and impact of target trial emulation. Multinational collaboration and data sharing across diverse sources will accelerate the generation of evidence, ultimately advancing medication safety.

CONCLUSION

Target trial emulation, leveraging real-world data, is a promising alternative when traditional clinical trials are not feasible. This approach promotes safer medication use and improves health outcomes for mothers and infants.

PLAIN LANGUAGE SUMMARY

Many clinical trials exclude pregnant women and infants, leaving critical gaps in understanding medication safety during pregnancy and early life. Target trial emulation, which applies clinical trial principles to real-world data, offers a promising alternative when traditional trials are not feasible. This method allows researchers to study how medications affect pregnant women and babies at different stages of pregnancy while also considering factors that change over time. While there are still challenges, like unmeasured factors and bias remain, target trial emulation helps fill these knowledge gaps. Future advancements, including AI, Open Science, enhanced data sharing, and international collaboration, can further enhance this method's ability to improve the safety of medications for mothers and infants worldwide.

Prevalence of systemic antibacterial use during pregnancy worldwide: A systematic review

OBJECTIVES

In this study, we aimed to systematically review the literature of the prevalence of systemic antibacterial use during pregnancy and to perform a descriptive analysis focused on methodological characteristics.

MATERIALS AND METHODS

This study was registered in PROSPERO under protocol number CRD42022376634. Medline, Embase, Scientific Electronic Library Online, Biblioteca Virtual em Saúde, Cumulative Index to Nursing and Allied Health Literature, and Web of Science databases were searched (published studies until November 3rd, 2022). Selected studies were population-based cross-sectional or cohort, carried out with pregnant women, and providing information about the prevalence of systemic antibacterial use at least in one trimester of pregnancy. Reviewers conducted in pairs the title and abstract screening, eligibility criteria check, and data extraction of selected studies. Quality appraisal was performed with an adapted version of the Joanna Briggs Institute Critical Appraisal Checklist for Prevalence Studies. Data of included studies were pooled into a graphical and tabular summary.

RESULTS

A total of 16,251,280 pregnant women and 5,169,959 pregnancy registers were identified. The prevalence estimates of systemic antibacterial use during pregnancy ranged from 2.0% (95%CI 2.0-2.0) to 64.3% (95%CI not reported) in the 79 included studies. The majority were performed in high-income countries (91.5%). Overall, the studies revealed considerable prevalence heterogeneity in terms of study type and dataset used. The 95% confidence intervals were not reported in 41% of studies.

CONCLUSION

The disparities in the prevalence of systemic antibacterial use during pregnancy can be related to methodological issues and different health policies. Lack of uniform databases and changes in data collection methods over time should be taken into account in public health strategy planning. The scarce evidence in low- and middle-income settings hampers the comprehensiveness of the global prevalence of antibacterial use during pregnancy.

Early-Life Antibiotic Exposure and Childhood Asthma Trajectories: A National Population-Based Birth Cohort

INTRODUCTION

Early-life antibiotic exposure is common and impacts the development of the child's microbiome and immune system. Information on the impacts of early-life antibiotics exposure on childhood asthma is lacking.

METHODS

This study examined associations between early-life (0-24 months) antibiotics exposure with childhood (6-15 years) asthma trajectories through the Australian Longitudinal Study of Australian Children (LSAC) and their linked data from the Pharmaceutical Benefits Scheme. Asthma phenotypes were derived by group-based trajectory modeling.

RESULTS

Of 5107 LSAC participants, 4318 were included in the final analyses (84.6% retention). Four asthma phenotypes were identified: Always-low-risk (79.0%), early-resolving asthma (7.1%), early-persistent asthma (7.9%), and late-onset asthma (6.0%). Any early-life antibiotic exposure increased risk 2.3-fold (95% CI: 1.47-3.67; p < 0.001) for early-persistent asthma among all children. In subgroup analyses, early-persistent asthma risk increased by 2.7-fold with any second-generation cephalosporin exposure, and by 2-fold with any β-lactam other than cephalosporin or macrolide exposure.

CONCLUSION

We concluded that early-life antibiotic exposure is associated with an increased risk of early-persistent childhood asthma. This reinforces scrutiny of early-life antibiotic use, particularly for common viral infections where no antibiotics are required.